Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities

Molecular Cancer Research

Volumn 8, Issue 10, 2010, Pages 1310-1318

  Ma, Xinrong ^a   Kundu, Namita ^a,b   Ioffe, Olga B ^a,b   Goloubeva, Olga ^a,b   Konger, Raymond ^d   Baquet, Claudia ^a,b   Gimotty, Phyllis ^e   Reader, Jocelyn ^a   Fulton, Amy M ^a,b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c BALTIMORE VA MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL 2 (8 CHLORO 10,11 DIHYDRODIBENZ[B,F][1,4]OXAZEPINE 10 CARBONYL)HYDRAZINE; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; MESSENGER RNA; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E RECEPTOR EP1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST METASTASIS; BREAST TUMOR; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RACE DIFFERENCE; TUMOR CELL;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NUCLEAR PROTEINS; PROGNOSIS; RECEPTORS, PROSTAGLANDIN E, EP1 SUBTYPE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

MURINAE;

EID: 78649667407     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0003     Document Type: Article

References (37)

1. Ristimaki A, Sivula A, Lundin M, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
2. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures properties and functions. Physiol Rev 1999;79:1193-226.
3. Fujino H, Regan JW. Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer? Trends Pharmacol Sci 2003;24:335-40.
4. Watanabe T, Satoh H, Togoh M, Taniguchi S, Hashimoto Y, Kurokawa K. Positive and negative regulation of cell proliferation through prostaglandin receptors in NIH-3T3 cells. J Cell Physiol 1996;69:401-9.
5. Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res 2002;62:28-32.
6. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 2001;9:1048-51.
7. Watanabe K, Kawamori T, Nakatsugi S, et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999;59:5093-6. (Pubitemid 29503965)
8. Kitamura T, Itoh M, Noda T, et al. Combined effects of prostaglandin E receptor subtype EP1 and subtype EP4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Cancer Sci 2003;94:618-21.
9. Ma X, Kundu N, Rifat S, Walser T, Fulton AM. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 2006;66:2923-7, PMID:16540639.
10. Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006;66:9794-7.
11. Kundu N, Ma X, Holt D, Goloubeva O, Ostrand-Rosenberg S, Fulton AM. Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat 2009;117:235-42.
12. Yang L, Huang Y, Porta R, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006;66:9665-72.
13. Thorat MA, Morimiya A, Mehrotra S, Konger R, Badve S. Prostanoid receptor EP1 expression in breast cancer. Mod Pathol 2008;21:15-21.
14. Fulton AM, Zhang S-Z, Chong YC. Role of the prostaglandin E receptor in mammary tumor metastasis. Cancer Res 1991;51:2047-50, PMID:1849040.
15. Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 1983;3:22-31.
16. Ma X, Norsworthy K, Kundu N, et al. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 2009;8:490-8.
17. 2 receptor: role in keratinocyte differentiation and expression in non-melanoma skin cancer. Prostaglandins Leukot Essent Fatty Acids 2009;81:279-90.
18. Selaru FM, Yin J, Olaru A, et al. An unsupervised approach to identify molecular phenotypic components influencing breast cancer features. Cancer Res 2004;64:1584-8.
19. 2 signaling pathway. J Biol Chem 2006;281:24831-46.
20. Simon MS, Severson RK. Racial differences in breast cancer survival: the interaction of socioeconomic status and tumor biology. Am J Obstet Gynecol 1997;176:S233-9.
21. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006;56:168-83.
22. Kawamori T, Uchiya N, Nakatsugi S, et al. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP1 antagonist, on breast cancer development. Carcinogenesis 2001;22:2001-4.
23. 2-dependent angiogenic switch in cyclooxygenase-2-induced breast cancer progression. Proc Natl Acad Sci 2004;101:591-6.
24. 2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab 2003;88:2810-6.
25. Subbaramaiah K, Hudis C, Chang SH, Hla T, Dannenberg AJ. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem 2008;283:3433-44.
26. Tober KL, Wilgus TA, Kusewitt DF, Thomas-Ahner JM, Maruyama T, Oberyszyn TM. Importance of the EP1 receptor in cutaneous UVB-induced inflammation and tumor development. J Invest Dermatol 2006;126:205-11.
27. Sung YM, He G, Fischer SM. Lack of expression of the EP2 but not the EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 2005;65:9304-11.
28. 2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003;289:265-74.
29. 2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003;278:35451-7.
30. Jain S, Chakraborty G, Raja R, Kale S, Kundu GC. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008;68:7750-9.
31. Robertson FM, Simeone A-M, Mazumdar A, et al. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exp Ther Oncol 2008;7:299-312.
32. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997;122:217-24.
33. Lee JL, Kim A, Kopelovich L, Bickers DR, Athar M. Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer. J Invest Dermatol 2005;125:818-25.
34. Gobeil F, Fortier A, Zhu T, et al. G-protein-coupled receptors signaling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol 2006;84:287-97.
35. 2, PAF and LPA1 receptors. Can J Physiol Pharmacol 2006;84:377-91.
36. Bhattacharya M, Peri KG, Almazan G, et al. Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci U S A 1998;95:15792-7.
37. Dore S. GPCR antagonists as an alternative to COX-2 inhibitors: a case for the PGE2 EP1 receptor. Trends Pharmacol Sci 2006;27:458-60.